Cerberus, Ampersand agree $3.1bn biotech exit
The private equity firms have agreed to sell Talecris Biotherapeutics, purchased for $590m in 2005, to Australian blood products company CSL.
The private equity firms have agreed to sell Talecris Biotherapeutics, purchased for $590m in 2005, to Australian blood products company CSL.
Copyright PEI Media
Not for publication, email or dissemination